Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kaken Files Japan NDA for Eschar Remover KMW-1
June 29, 2021
- Kissei Licenses Out South Korean Rights for Fostamatinib
June 29, 2021
- Novo’s Smart Insulin Pens Get Japan Approval, Launch in H1 2022
June 28, 2021
- Otsuka Seeks EU Nod for Lupus Nephritis Drug
June 28, 2021
- CellCept Gets Additional Nod for GVHD in HSCT: Chugai
June 28, 2021
- Sumitomo Dainippon Chief’s Pay Tops 100 Million Yen
June 28, 2021
- MSD Chief Wants Japan to Eliminate Disincentives Tied to Re-Pricing Rules as Keytruda Faces Repeated Cuts
June 28, 2021
- Sawai Expands Shipment Adjustments to 369 Products
June 28, 2021
- Biosimilar Momentum Unabated in Japan Even with Supply Concerns
June 25, 2021
- Japan Pharma Market Forecast to Decline through FY2025: IQVIA
June 25, 2021
- BAN2401 Gets FDA’s Breakthrough Therapy Tag: Eisai/Biogen
June 25, 2021
- Boehringer, Japan Cancer Foundation Join Hands for Oncology Research
June 24, 2021
- Shionogi President Earns 242 Million Yen in FY2020
June 24, 2021
- Daiichi Sankyo Chief Takes Home 170 Million Yen in FY2020: Securities Report
June 23, 2021
- Opdivo Expands Label for Combo Use with Avastin/Chemo in NSCLC
June 23, 2021
- Roche Diagnostics’ ALK CDx Ventana Approved for Alunbrig
June 23, 2021
- MSD Tops Foreign Pharma List in Japan in FY2020, but Big Players in a Melee
June 23, 2021
- FoundationOne OK’ed as a CDx for Opdivo/Keytruda’s MSI-High Use: Chugai
June 23, 2021
- Mochida Seeks Japan Approval of Once-Daily Epadel
June 23, 2021
- Nichi-Iko Halts Supplies of Some Edirol Generic Products, Re-Supply Expected for September
June 22, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…